1. Put yourself back in the financial crisis of 2008-09. With the information available by 2009, how would you evaluate Chens decision to invest $45 million to diversify RoboTech into medical robotics?
2. At the end of 2016, looking back over RoboTechs three years in the U.S. market, how well do you think it has done? In light of its management shortfalls, what would you suggest RoboTech should have done differently?
3. To move forward in 2017, what are the alternative strategic options for RoboTech? What are the pros and cons of each option?
4. What strategic option would you recommend RoboTech to take, and why? How should RoboTech implement it successfully?